Summit Therapeutics (SMMT) Tops Q4 EPS by 19c

Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.07), GBP0.19 better than the analyst estimate of (GBP0.26).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance